key: cord-0764586-9zf9mbzv
authors: Qaseem, Amir; Yost, Jennifer; Etxeandia-Ikobaltzeta, Itziar; Forciea, Mary Ann; Abraham, George M.; Miller, Matthew C.; Obley, Adam J.; Humphrey, Linda L.; Akl, Elie A.; Andrews, Rebecca; Dunn, Andrew; Haeme, Ray; Kansagara, Devan L.; P. Tschanz, CDR Mark
title: What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2)
date: 2022-01-25
journal: Ann Intern Med
DOI: 10.7326/m21-3272
sha: ec332421252a46ff1957233bd3e2767ce08b8a36
doc_id: 764586
cord_uid: 9zf9mbzv

DESCRIPTION: The Scientific Medical Policy Committee (SMPC) of the American College of Physicians (ACP) developed these living, rapid practice points to summarize the current best available evidence on the antibody response to SARS-CoV-2 infection and protection against reinfection with SARS-CoV-2. This is version 2 of the ACP practice points, which serves to update version 1, published on 16 March 2021. These practice points do not evaluate vaccine-acquired immunity or cellular immunity. METHODS: The SMPC developed this version of the living, rapid practice points based on an updated living, rapid, systematic review conducted by the Portland VA Research Foundation and funded by the Agency for Healthcare Research and Quality. PRACTICE POINT 1: Do not use SARS-CoV-2 antibody tests for the diagnosis of SARS-CoV-2 infection. PRACTICE POINT 2: Do not use SARS-CoV-2 antibody tests to predict the degree or duration of natural immunity conferred by antibodies against reinfection, including natural immunity against different variants. RETIREMENT FROM LIVING STATUS: Although natural immunity remains a topic of scientific interest, this topic is being retired from living status given the availability of effective vaccines for SARS-CoV-2 and widespread recommendations for and prevalence of their use. Currently, vaccination is the best clinical recommendation for preventing infection, reinfection, and serious illness from SARS-CoV-2 and its variants.

Updates to key questions in the living, rapid, systematic review are prioritized on the basis of identification of new evidence from literature surveillance that will likely substantially modify the conclusions or the certainty of evidence. Based on literature surveillance, the Portland VA Research Foundation and the SMPC determined that there was a signal to perform a focused update of key questions 2, 2a, 2b, 3, and 3a (large population-based studies that included uninfected comparison groups were published) and that the evidence for key questions 1, 1a, and 4 had not matured enough to evaluate the long-term persistence of antibodies, which would substantially modify the conclusions or certainty of evidence in the previous version. Consistent with methods for living systematic reviews and our living, rapid practice points (7) , the inclusion criteria were modified to include large longitudinal studies with control groups to evaluate the risk for reinfection, and key questions were modified for clarity (Appendix Table, available at Annals.org).

The evidence update (5, 6) identified 18 new studies (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) informing key questions 2, 2a, and 3, for which there were previously no studies that met the inclusion criteria in version 1 (3) . These studies were initiated before the emergence of the Delta and Omicron variants and before the U.S. Food and Drug Administration's emergency use authorization of vaccines late in 2020 (5, 6) . The new studies compared the risk for symptomatic reinfection (as a primary outcome) among adults with a recent SARS-CoV-2 infection with the risk for infection among adults without a recent infection, with "recent" defined as within 7 months of initial SARS-CoV-2 infection. These studies were designed to evaluate risk for symptomatic reinfection, with risk for asymptomatic reinfection as a secondary outcome. The new studies showed that patients with a recent SARS-CoV-2 infection have a substantially reduced risk for symptomatic reinfection (88% in the general population and 87% in health care workers) compared with those without a recent infection (key question 2) over follow-up of 4 to 13 months. There is also protection for asymptomatic reinfections, but the evidence is unclear about whether the degree of protection for asymptomatic reinfections is as high as it is for symptomatic reinfections. No evidence was identified on threshold levels of antibodies needed to confer protection from reinfection or the contribution of the antibody response to this protection (key question 2b). The systematic review update did not identify evidence from included studies on whether risk for reinfection varied by patient comorbidities (including immunosuppression) or by viral variants other than the Alpha variant (including the Delta and Omicron variants) (key question 2a), or whether the variation in the duration of protection varies by patient or clinical characteristics (key question 3a).

Evidence continues to emerge about the antibody response to SARS-CoV-2 infection and protection against Table 1 

Evidence is emerging about the antibody response after initial infection with SARS-CoV-2, as well as protection against future reinfection with SARS-CoV-2. These practice points do not evaluate vaccine-acquired immunity or cellular immunity. Vaccination is currently the best clinical recommendation for preventing SARS-CoV-2 infection or reinfection (1, 2) . The following practice points are based on the current best available evidence.

What has changed in the practice points since the last version? 

Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 future reinfection. The following practice points are based on the current best available evidence. The Figure, Table 2 , and the accompanying systematic review (5, 6) summarize changes in the findings. Table  3 presents clinical considerations, and Table 4 identifies evidence gaps. We have retired Practice Point 2 from version 1, which stated, "Antibody tests can be useful for the purpose of estimating community prevalence of SARS-CoV-2 infection." The relevance of this statement is now limited given the increase in vaccinations in the United States and because antibody tests cannot differentiate antibodies that develop due to past SARS-CoV-2 infection from those that develop due to vaccination.

Practice Point 1: Do not use SARS-CoV-2 antibody tests for the diagnosis of SARS-CoV-2 infection

Studies included in the version 1 systematic review evaluated the prevalence, levels, and duration of different types of antibodies after symptom onset or confirmation of SARS-CoV-2 infection with a positive RT-PCR result (3) . These studies showed that most patients develop detectable antibodies after SARS-CoV-2 infection; however, the timing of when different antibodies peak and how long they remain detectable may vary (low to moderate certainty). Furthermore, the antibody response may vary by age, sex, race/ethnicity, and the severity of the initial infection (low certainty), and the evidence is very uncertain (insufficient) as to whether the response varies by comorbidities or type of immunoassay. In addition, the diagnostic test characteristics (for example, sensitivity, specificity, and accuracy) vary substantially across the antibody tests used in the included studies (3) (4) (5) (6) , contributing to differing risks for false-negative and false-positive results (94, 95) . For these reasons, based on the studies included in version 1, antibody tests should not be used for the diagnosis of SARS-CoV-2 infection. The evidence search and assessment were conducted by the Portland VA Research Foundation (3, 5, 6) . The evidence search was updated through 22 September 2021. PCR = polymerase chain reaction. * Observational studies include studies estimating seroprevalence among a given population that includes a small subpopulation known to have SARS-CoV-2 infection; cross-sectional or cohort studies characterizing the antibody response among adults with SARS-CoV-2 infection; and large, populationbased observational (cohort, case-control) studies comparing risk for reinfection in adults with and without recent SARS-CoV-2 infection (3, 5, 6) . Immunoassay validation studies include those validating the diagnostic performance of 1 or more immunoassays (3). Protection against reinfection remains >80% for ≥7 months (8, 9, 11, 15, 18, 19, 22, 24) High Protection against reinfection may remain >80% for 7 to 10 months (11, 15, 18, 19, 22, 24) Low Very uncertain about protection against reinfection beyond 10 months (11 Poor quality: methodologically flawed study with high risk of bias. Unclear quality: methodological soundness could not be determined. † "Insufficient" indicates that confidence is inadequate to assess the likelihood of benefit (benefit minus harm) of an intervention or its effect on a health outcome. "Low" indicates that confidence in the effect is limited, as the true effect may be substantially different from the estimated effect. "Moderate" indicates that confidence in the effect is moderate, as the true effect is likely close to the estimated effect, but there is a sizable possibility that it is substantially different. "High" indicates confidence that the true effect is close to the estimated effect. Assessments regarding antibody prevalence were focused on results from seroprevalence, cross-sectional, and cohort studies rather than results from immunoassay validation studies (which provide less reliable estimates). For all other outcomes of interest, results from all studies were incorporated into the assessments (3). ‡ The certainty of evidence was not assessed for these comparisons.

Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2

Annals.org Annals of Internal Medicine Practice Point 2: Do not use SARS-CoV-2 antibody tests to predict the degree or duration of natural immunity conferred by antibodies against reinfection, including natural immunity against different variants Updated Rationale Because measuring antibodies is an approach for evaluating the immune response, questions arise about the role of antibody testing in assessing natural immunity and protection from reinfection after SARS-CoV-2 infection. Although new evidence (18 new studies) has emerged addressing the risk for reinfection among adults with recent SARS-CoV-2 infection, several important evidence gaps remain in the new body of evidence that limit the clinical role of antibody testing ( Table 4) .

Low-to moderate-certainty evidence showed that patients with asymptomatic and symptomatic initial infections develop detectable antibodies (3), and high-certainty evidence from new studies showed that recent initial SARS-CoV-2 infection reduced the risk for symptomatic reinfection by 84% to 90% in adults over follow-up ranging from 4 to 13 months. This degree of protection may be similar across age groups (low certainty), with the Alpha variant (low certainty), in persons in the general population and health care workers, and does not vary according to sex (high certainty). However, these studies do not establish that antibodies are primarily responsible for the observed natural immunity because none of the new studies examined the relationship between antibody levels and degree of natural immunity, including threshold levels of detectable SARS-CoV-2 antibodies necessary to confer natural immunity. Furthermore, the included studies were conducted before the Delta and Omicron variants became the dominant circulating strains. However, the systematic review identified 3 studies that were not yet fully reported (96) or were longitudinal uncontrolled studies (97, 98) and thus did not meet the inclusion criteria; these studies suggest that recent SARS-CoV-2 infection reduced risk for reinfection in adults after the Delta variant became the dominant strain.

It is important to note that none of the new included studies reported on the variation in risk for reinfection in patients who are immunocompromised or have other comorbidities, and evidence is very uncertain (insufficient) about other factors that may modify risk for reinfection, including initial antibody levels and race/ethnicity. Evidence is also conflicting about risk for reinfection in patients who had an asymptomatic initial infection (5, 6) ; studies show that risk for reinfection may be higher for patients who had a mild or asymptomatic initial infection compared with those who had a symptomatic initial infection (low certainty). Although evidence suggests a high degree of protection (>80%) against symptomatic SARS-CoV-2 reinfection in the short term (high certainty for up to 7 months and low certainty for 7 to 10 months), the duration of protection beyond 10 months is very uncertain (insufficient), and follow-up in the included studies is constrained by time elapsed since the beginning of the pandemic. Finally, none of the included studies reported on how the duration of protection might vary by such factors as variant strains, initial antibody levels, and patient characteristics.

Despite evidence that patients develop detectable antibodies (3) and have reduced risk for reinfection after initial SARS-CoV-2 infection, knowledge about the direct association of the antibody response and the degree of natural immunity to SARS-CoV-2 is still limited. In light of these evidence gaps, and considering previously reported insufficient (very uncertain) evidence (3) about the unintended consequences of antibody testing, we advise against antibody testing to evaluate for natural immunity. Patients with current or previous SARS-CoV-2 infection should continue to follow recommended infection prevention and control procedures to slow and reduce transmission of the virus (92, 93, 99) .

The SMPC is retiring the ACP living, rapid practice points on the antibody response to SARS-CoV-2 infection and protection against reinfection with SARS-CoV-2 from living status (7), given the widespread availability and use of effective vaccines against SARS-CoV-2 infection in the United States. Vaccination is currently the best clinical recommendation for prevention of SARS-CoV-2 infection Table 3 . Clinical Considerations Updated: These practice points only evaluate the antibody-mediated natural immune response and do not address the role of other important natural or acquired immune responses, such as cell-mediated immunity or artificial immunity conferred by vaccination. New: Given uncertainty about the level and duration of protection that natural immunity confers, vaccination is currently the best clinical recommendation for protection against SARS-CoV-2 infection or reinfection (1, 2) . Updated: The public should continue to follow recommended infection prevention and control procedures to slow and reduce the transmission of SARS-CoV-2 infection (92, 93).

Studies are needed to understand why some patients with PCRconfirmed SARS-CoV-2 infection do not develop antibodies. New: Research is needed to determine the threshold levels of detectable SARS-CoV-2 antibodies that are necessary to provide continued protection against reinfection (antibodies from prior infection or vaccination) and to identify the most valid and reliable tests to determine these levels. Updated: Research is needed to understand the associations between antibody response and patient characteristics (age, sex, race/ethnicity, comorbidities, immunocompromised status, presence of symptoms, and severity of initial infection). Updated: Research is needed to determine how long protection from reinfection is conferred by antibodies and whether this varies by clinical and patient characteristics. New: The included studies were not entirely representative of patients who may be disproportionately affected by COVID-19. Research is needed to determine whether there are differences in protection against reinfection based on patient characteristics (age, race/ethnicity, comorbidities, and immunocompromised status). New: Research is needed to determine whether there are differences in protection against reinfection based on initial antibody levels, severity of initial infection, and SARS-CoV-2 variants. PCR = polymerase chain reaction.

Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 and reinfection, including from currently circulating viral variants (1, 2) . Note: The practice points are meant to guide care based on the best available evidence and may not apply to all patients or individual clinical situations. They should not be used as a replacement for a clinician's judgment. Any reference to a product or process contained in a practice point is not intended as an endorsement of any specific commercial product. All practice points are considered automatically withdrawn or invalid 5 years after publication or once an update has been issued.

Financial Support: Financial support for the development of the practice points comes exclusively from the ACP operating budget.

Disclosures: Disclosures can be viewed at www.acponline.org/ authors/icmje/ConflictOfInterestForms.do?msNum=M21-3272. All financial and intellectual disclosures of interest were declared, and potential conflicts were discussed and managed. Dr. Jokela participated in discussion of the practice points but was recused from authorship and voting due to a moderatelevel conflict of interest (authored recent relevant publications). Dr. Marcucci participated in the discussion of the practice points but was recused from authorship and voting due to a moderate-level conflict of interest (author of relevant systematic review). A record of disclosures of interest and management of conflicts is kept for each SMPC meeting and conference call and can be viewed at www.acponline.org/about-acp/who-weare/leadership/boards-committees-councils/scientific-medicalpolicy-committee/disclosure-of-interests-and-conflict-of-interestmanagement-summary-for-scientific-medical-policy.

Advisory Committee on Immunization Practices. COVID-19 ACIP Vaccine Recommendations

World Health Organization. COVID-19 advice for the public: Getting vaccinated

Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living review

Scientific Medical Policy Committee of the American College of Physicians. What is the antibody response and role in conferring natural immunity after SARS-CoV-2 infection? Rapid, living practice points from the American College of Physicians (version 1)

Risk of reinfection after SARS-CoV-2. Living rapid review for ACP practice points on the role of the antibody response in conferring immunity following SARS-CoV-2 infection

Risk of Reinfection From SARS-CoV-2 -An Update of an Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Living Rapid Review. (Prepared by the Scientific Resource Center under contract no. 290-2017-0003.) AHRQ publication no. 21-EHC034. Agency for Healthcare Research and Quality

Scientific Medical Policy Committee of the American College of Physicians. The development of living, rapid practice points: summary of methods from the Scientific Medical Policy Committee of the American College of Physicians

The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

SARS-CoV-2 infection and reinfection in a seroepidemiological workplace cohort in the United States. medRxiv. Preprint posted online 6

Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: a three-month nationwide experience from Israel. medRxiv. Preprint posted online 24

SARS-CoV-2 infection rates of antibody-positive compared with antibodynegative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Association of SARS-CoV-2 seropositive antibody test with risk of future infection

Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes

Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long term care facilities (VIVALDI study). medRxiv. Preprint posted online 10

Risk of reinfection after seroconversion to SARS-CoV-2: a population-based propensity-score matched cohort study

Oxford University Hospitals Staff Testing Group. Antibody status and incidence of SARS-CoV-2 infection in health care workers

The risk of symptomatic reinfection during the second COVID-19 wave in individuals previously exposed to SARS-CoV-2. medRxiv. Preprint posted online

SARS-CoV-2 re-infection risk in Austria

Risk of SARS-CoV-2 reinfection in a university student population

Reinfection rates among patients who previously tested positive for coronavirus disease 2019: a retrospective cohort study

Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy

Head-to-head accuracy comparison of three commercial COVID-19 IgM/IgG serology rapid tests

Geneva Centre for Emerging Viral Diseases. Diagnostic accuracy of Augurix

IgG serology rapid test

Dynamic anti-spike protein antibody profiles in COVID-19 patients

Efficacy of a test-retest strategy in residents and health care personnel of a nursing home facing a COVID-19 outbreak

Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers

Clinical features and antibody response of patients from a COVID-19 treatment hospital in Wuhan

Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production

SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts

Diagnostic performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus disease 2019

Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection

Study of antibody-based rapid card test in COVID-19 patients admitted in a tertiary care COVID hospital in Southern Rajasthan

Saint-Louis CORE (COvid REsearch) group. Evaluation of the COVID-19 IgG/IgM rapid test from Orient Gene Biotech

Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France

Detection of IgM and IgG antibodies in patients with coronavirus disease 2019

Temporal antibody responses to SARS-CoV-2 in patients of coronavirus disease

Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19

IgM and IgG antibodies: an Italian experience

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with pneumonic COVID-19 patients

Dynamics of CD4 T cell and antibody responses in COVID-19 patients with different disease severity

Factors of severity in patients with COVID-19: cytokine/chemokine concentrations, viral load, and antibody responses

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19

Detection of IgG antibody during the follow-up in patients with COVID-19 infection

Changes in serum virus-specific IgM/ IgG antibody in asymptomatic and discharged patients with reoccurring positive COVID-19 nucleic acid test (RPNAT)

A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients

Analysis of adjunctive serological detection to nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis

Patterns of IgG and IgM antibody response in COVID-19 patients

Magnitude and kinetics of anti-severe acute respiratory syndrome coronavirus 2 antibody responses and their relationship to disease severity

Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity

SARS-CoV-2 infections and serologic responses from a sample of U.S. Navy service members-USS Theodore Roosevelt

Lack of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a large cohort of previously infected persons

Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Healthcare staff perceptions and misconceptions regarding antibody testing in the United Kingdom: implications for the next steps for antibody screening

Sustained SARS-CoV-2 nucleocapsid antibody levels in nonsevere COVID-19: a populationbased study

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Factors affecting antibody response to SARS-CoV-2 in patients with severe COVID-19

Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/ IgG

Dynamic changes of antibodies to SARS-CoV-2 in COVID-19 patients at early stage of outbreak

Stock da Cunha T, Gomá-Garc es E, Avello A, et al. The spectrum of clinical and serological features of COVID-19 in urban hemodialysis patients

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes. med. Rxiv. 2020

Anti-SARS-CoV-2 antibody responses in convalescent plasma donors are increased in hospitalized patients; subanalyses of a phase 2 clinical study. Microorganisms

Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2

Performance of severe acute respiratory syndrome coronavirus 2 antibody assays in different stages of infection: comparison of commercial enzyme-linked immunosorbent assays and rapid tests

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. medRxiv. Preprint posted online 29

Longitudinal dynamics of the neutralizing antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

Combination of serological total antibody and RT-PCR test for detection of SARS-COV-2 infections

Screening for SARS-CoV-2 antibodies in convalescent plasma (CCP) in Brazil: results from a voluntary convalescent donor program

Monitoring antibody response following SARS-CoV-2 infection: diagnostic efficiency of 4 automated immunoassays

Antibody detection and dynamic characteristics in patients with coronavirus disease 2019

Dysfunction of adaptive immunity is related to severity of COVID-19: a retrospective study

Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

Novel Coronavirus Outbreak Research Team. Viral dynamics and immune correlates of coronavirus disease 2019 (COVID-19) severity

Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19

A comparative study of the laboratory features of COVID-19 and other viral pneumonias in the recovery stage

Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019

Analysis of the application value of serum antibody detection for staging of COVID-19 infection

Centers for Disease Control and Prevention. Interim Public Health Recommendations for Fully Vaccinated People

Testing for SARS-CoV-2 antibodies

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. medRxiv. Preprint posted online 25

Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination-Kentucky

Outbreak of SARS-CoV-2 B.1.617.2 (Delta) variant infections among incarcerated persons in a federal prison-Texas

Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2

Analysis and interpretation of the data

Drafting of the article

Administrative, technical, or logistic support: I. Etxeandia-Ikobaltzeta, A. Qaseem

Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Appendix Do the levels and durability of detectable antibodies vary by patient characteristics (for example, age, sex, race/ethnicity, and comorbidities), COVID-19 severity (severity of the initial infection), presence of symptoms, time from symptom onset, or the characteristics of the immunoassay (sensitivity, specificity)? KQ 2Do anti-SARS-CoV-2 antibodies confer natural immunity against reinfection?What is the risk for reinfection with SARS-CoV-2 among adults with prior SARS-CoV-2 infection? Revised to include studies in which infection (cohort allocation) was documented by PCR (or by a combination of PCR and antibody testing) rather than by seroconversion or presumed seroconversion only, as well as to address magnitude of protection against future reinfection KQ 2a Does natural immunity vary by such factors as initial antibody levels, patient characteristics, presence of symptoms, or severity of disease?Does the risk for reinfection vary by patient characteristics (for example, age, sex, race/ethnicity, and comorbidities), severity of the initial infection, initial antibody levels, or SARS-CoV-2 variants? Revised to include studies in which infection (cohort allocation) was documented by PCR (or by a combination of PCR and antibody testing) rather than by seroconversion or presumed seroconversion only, as well as to address the magnitude of protection against future reinfection; modified to also assess variation by SARS-CoV-2 variants KQ 2bIs there a threshold level of detectable anti-SARS-CoV-2 antibodies necessary to confer natural immunity, and if so, does this threshold vary by patient characteristics (for example, age, sex, race/ethnicity, and comorbidities)?No changes KQ 3 If anti-SARS-CoV-2 antibodies confer natural immunity against reinfection, how long does this immunity last?What is the duration of protection against reinfection among adults with prior SARS-CoV-2 infection? Revised to include studies in which infection (cohort allocation) was documented by PCR (or by a combination of PCR and antibody testing) rather than by seroconversion or presumed seroconversion only KQ 3aDoes the duration of natural immunity vary by such factors as initial antibody levels, patient characteristics, presence of symptoms, or severity of disease?Does the duration of protection vary by patient characteristics (for example, age, sex, race/ethnicity, and comorbidities), severity of initial infection, initial antibody levels, SARS-CoV-2 variants, or case identification method (for example, surveillance, symptomatic testing only)? Rephrased for clarity; modified to also assess variation by SARS-CoV-2 variants and case identification method KQ 4 What are the unintended consequences of antibody testing after SARS-CoV-2 infection?No changes KQ = key question; PCR = polymerase chain reaction; RT-PCR = reverse transcriptase polymerase chain reaction. * Language modifications are in boldface.